Consumer health products validation startup Radicle Science has added a pair of high-profile team members with strong credentials in the health and humanitarian fields, building on its rapid rise to industry relevance in less than a year.
Since securing its initial seed funding in the fourth quarter of 2020, Radicle Science has surpassed numerous major milestones with accelerating momentum in the first three quarters of 2021.
The company is a certified healthtech B-corp, a hard-to-receive designation that’s means it balances profits with purpose. The certification is a statement of what a company stands for. Radicle Science sees itself in a transformative role in the work of validating consumer health products for the first time.
The company’s “Radicle Vision” is a future where affordable, accessible, consumer health products are trusted by patients, recommended by healthcare providers, reimbursed by insurance and used as widely as pharmaceutical drugs.
Notably, this month the company welcomed a medical doctor as the new chair of the Radicle Science Advisory Board, Dr. Peter H. Diamandis. Recently named by Fortune magazine as one of the “World’s 50 Greatest Leaders,” Diamandis is the founder and executive chair of the XPRIZE Foundation, which leads the world in running large-scale competitions to develop technologies that benefit humanity.
He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world’s leaders on exponentially growing technologies.
Radicle Science also announced the addition of Dr. Sheldon Borkin as the company’s new CTO, who joined in September. Borkin has been a technical and business leader at numerous start-ups and contributed his expertise to multiple IPOs. While at WebMD from startup through IPO to $1 billion in annual revenue, he held multiple senior technical and leadership roles, including chief security officer.
CBD Validation Partnership
The two new leadership additions follow the news of the newly formed alliance between Radicle Science and Open Book Extracts (OBX), a leading ingredient manufacturer and product developer of cannabinoid-enabled products, to advance the development of market-leading, scientifically validated CBD and other cannabinoid products, and the launch of multiple rigorous scientific studies on cannabinoid effectiveness.
Diamandis praised Radicle Science founders Executive Chairwoman Pelin Thorogood and CEO Jeff Chen, along with the team who’s joined their movement, calling them brilliant, passionate and inspiring.
“Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. “Radicle Science has the potential to help dematerialize, demonetize and democratize clinical trials, and unlock a future of meaningful and abundant health products directly accessible by all.”
Chen called Diamandis an exceptional global leader with a bold trans-disciplinary approach that will help Radicle achieve its audacious vision. He cited Borkin’s wealth of experience in analytics, agile software development and healthtech as being critical to Radicle Science’s plans to continue to scale rapidly.
More information about the Radicle Science-OBX alliance and the company’s ongoing studies is available online at the company’s Radicle Resources page.